Back to search
FDAFDA · Food and drugs·Recall number Z-2880-2026

Syva Emit Disopyramide Assay Enzyme Immunoassay, Lidocaine SMN 10445370 Catalog No 6N319UL

Published August 12, 2026 · Recall initiated: June 26, 2026

Summary

FDA records medical device Class III recall Z-2880-2026, published August 12, 2026 and initiated June 26, 2026. Recalling firm: Siemens Healthcare Diagnostics, Inc.; Status: Ongoing; Reported quantity: 8 US; 44 OUS; Lot: UDI-DI 00842768001406 Lot U1. Class III means the product is not likely to cause adverse health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Out-of-specification sodium azide concentration in Syva Emit Disopyramide Enzyme Immunoassay Calibrator Lot U1. While the assay results were not impacted, the overall health risk to lab technicians due to this issue is low, as exposure is limited by small volumes and a 0.2% post-reconstitution sodium azide concentration, with the worst outcome being mild skin or eye irritation and no serious harm anticipated.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Siemens Healthcare Diagnostics, Inc.
Distributor
Worldwide - US Nationwide distribution in the states of CA and VA. The country of Japan.
Lot
UDI-DI 00842768001406 Lot U1
Risk classification
Class III
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Syva Emit Disopyramide Assay Enzyme Immunoassay, Lidocaine SMN 10445370 Catalog No 6N319UL recalled?

Yes. FDA published recall Z-2880-2026 on August 12, 2026. Reported hazard: Out-of-specification sodium azide concentration in Syva Emit Disopyramide Enzyme Immunoassay Calibrator Lot U1. While the assay results were not impacted, the overall health risk to lab technicians due to this issue is low, as exposure is limited by small volumes and a 0.2% post-reconstitution sodium azide concentration, with the worst outcome being mild skin or eye irritation and no serious harm anticipated.

What should I do if I have this product?

Voluntary: Firm initiated · Letter